LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Detection Method Developed for Polymyxin-Resistant Enterobacteria

By LabMedica International staff writers
Posted on 01 Jun 2016
Image: Representative results of the rapid polymyxin NP [Nordmann/Poirel] test. Non-inoculated wells are shown as controls (first column). The rapid polymyxin NP test was performed with a reference colistin-susceptible isolate (second column) and with a reference colistin-resistant isolate (third column) in a reaction medium without (upper row) and with (lower row) colistin (Photo courtesy of the University of Fribourg).
Image: Representative results of the rapid polymyxin NP [Nordmann/Poirel] test. Non-inoculated wells are shown as controls (first column). The rapid polymyxin NP test was performed with a reference colistin-susceptible isolate (second column) and with a reference colistin-resistant isolate (third column) in a reaction medium without (upper row) and with (lower row) colistin (Photo courtesy of the University of Fribourg).
Among the most clinically significant multidrug-resistant bacteria are carbapenemase-producing Enterobacteriaceae, yet these bacteria usually remain susceptible to polymyxins, so interest in polymyxins has been renewed worldwide.

A rapid test has been developed that detects glucose metabolization associated with bacterial growth in the presence of a defined concentration of colistin or polymyxin B. The standard reference technique for determining susceptibility to polymyxins is broth microdilution, which requires fastidious attention and at least 24 hours to perform.

Microbiologists at the University of Fribourg (Switzerland) developed the rapid polymyxin Nordmann/Poirel (NP) test that detects bacterial growth in the presence of a defined concentration of a polymyxin. Bacterial growth detection (or absence) is based on carbohydrate metabolism. Acid formation associated with carbohydrate metabolism in Enterobacteriaceae can be observed through the color change of a pH indicator. This test is rapid taking less than two hours and easy to perform.

To evaluate the performance of the rapid polymyxin NP test, the team used 200 isolates collected from clinical samples worldwide. This collection included 135 Enterobacteriaceae isolates resistant to polymyxin: five isolates of intrinsically polymyxin-resistant species and 130 isolates of various enterobacterial species with acquired resistance to polymyxins. The rapid polymyxin NP test uses two reagents and solutions: stock solutions of polymyxins and rapid polymyxin NP solution.

The sensitivity and specificity of the rapid NP test were 99.3% and 95.4%, respectively, compared with the standard broth microdilution method. By reading the color change of the wells every hour, the scientists determined that final results were obtained two hours after incubation when the tray was incubated at 35 ± 2 °C under an ambient atmosphere. However, positive results with frank color change were obtained as early as one hour after incubation for Klebsiella spp. and Escherichia coli isolates. Half of the Enterobacter spp. isolates gave positive results within 60 minutes of incubation and the other half within 120 minutes.

The authors concluded that the new test is inexpensive, easy to perform, sensitive, specific, and can be completed in less than two hours. It could be useful in countries facing endemic spread of carbapenemase producers and for which polymyxins are last-resort drugs. The study was published in the June 2016 issue of the journal Emerging Infectious Diseases.

Related Links:
University of Fribourg


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more